Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Barberà JA[au]:

Pulmonary hypertension in chronic lung diseases. Seeger W et al. J Am Coll Cardiol. (2013)

Pulmonary hypertension due to left heart diseases. Vachiéry JL et al. J Am Coll Cardiol. (2013)

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. Galiè N et al. N Engl J Med. (2015)

Search results

Items: 1 to 50 of 250

1.

Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension.

White RJ, Vonk-Noordegraaf A, Rosenkranz S, Oudiz RJ, McLaughlin VV, Hoeper MM, Grünig E, Ghofrani HA, Chakinala MM, Barberà JA, Blair C, Langley J, Frost AE.

Respir Res. 2019 Sep 12;20(1):208. doi: 10.1186/s12931-019-1180-1.

2.

Pulmonary vascular density: comparison of findings on computed tomography imaging with histology.

Rahaghi FN, Argemí G, Nardelli P, Domínguez-Fandos D, Arguis P, Peinado VI, Ross JC, Ash SY, de La Bruere I, Come CE, Diaz AA, Sánchez M, Washko GR, Barberà JA, San José Estépar R.

Eur Respir J. 2019 Aug 15;54(2). pii: 1900370. doi: 10.1183/13993003.00370-2019. Print 2019 Aug.

PMID:
31196942
3.

Therapeutic effects of soluble guanylate cyclase stimulation on pulmonary hemodynamics and emphysema development in guinea pigs chronically exposed to cigarette smoke.

Paul T, Blanco I, Aguilar D, Tura-Ceide O, Bonjoch C, Smolders VF, Peinado VI, Barberà JA.

Am J Physiol Lung Cell Mol Physiol. 2019 Aug 1;317(2):L222-L234. doi: 10.1152/ajplung.00399.2018. Epub 2019 Jun 5.

PMID:
31166128
4.

Progenitor cell mobilisation and recruitment in pulmonary arteries in chronic obstructive pulmonary disease.

Tura-Ceide O, Pizarro S, García-Lucio J, Ramírez J, Molins L, Blanco I, Torralba Y, Sitges M, Bonjoch C, Peinado VI, Barberà JA.

Respir Res. 2019 Apr 16;20(1):74. doi: 10.1186/s12931-019-1024-z.

5.

Genetic linkage analysis of a large family identifies FIGN as a candidate modulator of reduced penetrance in heritable pulmonary arterial hypertension.

Puigdevall P, Piccari L, Blanco I, Barberà JA, Geiger D, Badenas C, Milà M, Castelo R, Madrigal I.

J Med Genet. 2019 Jul;56(7):481-490. doi: 10.1136/jmedgenet-2018-105669. Epub 2019 Mar 20.

PMID:
30894412
6.

Metabolic Alterations in Cardiopulmonary Vascular Dysfunction.

Smolders VF, Zodda E, Quax PHA, Carini M, Barberà JA, Thomson TM, Tura-Ceide O, Cascante M.

Front Mol Biosci. 2019 Jan 22;5:120. doi: 10.3389/fmolb.2018.00120. eCollection 2018. Review.

7.

The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension.

Newnham M, South K, Bleda M, Auger WR, Barberà JA, Bogaard H, Bunclark K, Cannon JE, Delcroix M, Hadinnapola C, Howard LS, Jenkins D, Mayer E, Ng C, Rhodes CJ, Screaton N, Sheares K, Simpson MA, Southwood M, Su L, Taboada D, Traylor M, Trembath RC, Villar SS, Wilkins MR, Wharton J, Gräf S, Pepke-Zaba J, Laffan M, Lane DA, Morrell NW, Toshner M.

Eur Respir J. 2019 Mar 28;53(3). pii: 1801805. doi: 10.1183/13993003.01805-2018. Print 2019 Mar.

8.

Effect of pulmonary artery denervation in postcapillary pulmonary hypertension: results of a randomized controlled translational study.

Garcia-Lunar I, Pereda D, Santiago E, Solanes N, Nuche J, Ascaso M, Bobí J, Sierra F, Dantas AP, Galán C, San Antonio R, Sánchez-Quintana D, Sánchez-González J, Barberá JA, Rigol M, Fuster V, Ibáñez B, Sabaté M, García-Álvarez A.

Basic Res Cardiol. 2019 Jan 11;114(2):5. doi: 10.1007/s00395-018-0714-x.

PMID:
30635778
9.

ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension.

Grünig E, Eichstaedt C, Barberà JA, Benjamin N, Blanco I, Bossone E, Cittadini A, Coghlan G, Corris P, D'Alto M, D'Andrea A, Delcroix M, de Man F, Gaine S, Ghio S, Gibbs S, Gumbiene L, Howard LS, Johnson M, Jurevičienė E, Kiely DG, Kovacs G, MacKenzie A, Marra AM, McCaffrey N, McCaughey P, Naeije R, Olschewski H, Pepke-Zaba J, Reis A, Santos M, Saxer S, Tulloh RM, Ulrich S, Vonk Noordegraaf A, Peacock AJ.

Eur Respir J. 2019 Feb 28;53(2). pii: 1800332. doi: 10.1183/13993003.00332-2018. Print 2019 Feb.

PMID:
30578391
10.

Pulmonary hypertension in chronic lung disease and hypoxia.

Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, Olsson KM, Peacock AJ, Pepke-Zaba J, Provencher S, Weissmann N, Seeger W.

Eur Respir J. 2019 Jan 24;53(1). pii: 1801914. doi: 10.1183/13993003.01914-2018. Print 2019 Jan.

11.

Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial.

Vachiéry JL, Galiè N, Barberá JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Blair C, Miller KL, Langley J, Rubin LJ; AMBITION Study Group.

J Heart Lung Transplant. 2019 Feb;38(2):194-202. doi: 10.1016/j.healun.2018.11.006. Epub 2018 Nov 22.

12.

Determinants of the Appearance and Progression of Early-Onset Chronic Obstructive Pulmonary Disease in Young Adults. A Case-Control Study with Follow-up.

Borràs-Santos A, Garcia-Aymerich J, Soler-Cataluña JJ, Vigil Giménez L, Gea Guiral J, Rodríguez Chiaradía D, Pascual-Guardia S, Marcos Rodríguez PJ, Alvarez Martinez CJ, Casanova Macario C, López-Campos JL, Carrasco Hernández L, Martínez-González C, Santos-Pérez S, Peces-Barba G, Molina Paris J, Román Rodríguez M, Barberà JA, Faner R, Agustí A, Cosío BG; en representación del Grupo Investigador del estudio EARLY COPD.

Arch Bronconeumol. 2019 Jun;55(6):312-318. doi: 10.1016/j.arbres.2018.09.007. Epub 2018 Nov 11. English, Spanish.

13.

Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk score.

Frost AE, Hoeper MM, Barberá JA, Vachiery JL, Blair C, Langley J, Rubin LJ.

J Heart Lung Transplant. 2018 Dec;37(12):1410-1417. doi: 10.1016/j.healun.2018.07.001. Epub 2018 Sep 9.

PMID:
30209017
14.

Groundwater dynamics in a hydrologically-modified alpine watershed from an ancient managed recharge system (Sierra Nevada National Park, Southern Spain): Insights from hydrogeochemical and isotopic information.

Barberá JA, Jódar J, Custodio E, González-Ramón A, Jiménez-Gavilán P, Vadillo I, Pedrera A, Martos-Rosillo S.

Sci Total Environ. 2018 Nov 1;640-641:874-893. doi: 10.1016/j.scitotenv.2018.05.305. Epub 2018 Jun 5.

PMID:
29879673
15.

MicroRNA Dysregulation in Pulmonary Arteries from Chronic Obstructive Pulmonary Disease. Relationships with Vascular Remodeling.

Musri MM, Coll-Bonfill N, Maron BA, Peinado VI, Wang RS, Altirriba J, Blanco I, Oldham WM, Tura-Ceide O, García-Lucio J, de la Cruz-Thea B, Meister G, Loscalzo J, Barberà JA.

Am J Respir Cell Mol Biol. 2018 Oct;59(4):490-499. doi: 10.1165/rcmb.2017-0040OC.

PMID:
29757677
16.

Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype?

Kovacs G, Agusti A, Barberà JA, Celli B, Criner G, Humbert M, Sin DD, Voelkel N, Olschewski H.

Am J Respir Crit Care Med. 2018 Oct 15;198(8):1000-1011. doi: 10.1164/rccm.201801-0095PP. No abstract available.

PMID:
29746142
17.

Imbalance between endothelial damage and repair capacity in chronic obstructive pulmonary disease.

García-Lucio J, Peinado VI, de Jover L, Del Pozo R, Blanco I, Bonjoch C, Coll-Bonfill N, Paul T, Tura-Ceide O, Barberà JA.

PLoS One. 2018 Apr 19;13(4):e0195724. doi: 10.1371/journal.pone.0195724. eCollection 2018.

18.

Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases: Highlights from basic research to therapy.

Huertas A, Guignabert C, Barberà JA, Bärtsch P, Bhattacharya J, Bhattacharya S, Bonsignore MR, Dewachter L, Dinh-Xuan AT, Dorfmüller P, Gladwin MT, Humbert M, Kotsimbos T, Vassilakopoulos T, Sanchez O, Savale L, Testa U, Wilkins MR.

Eur Respir J. 2018 Apr 4;51(4). pii: 1700745. doi: 10.1183/13993003.00745-2017. Print 2018 Apr. Review.

PMID:
29545281
19.

Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Summary of Recommendations.

Barberà JA, Román A, Gómez-Sánchez MÁ, Blanco I, Otero R, López-Reyes R, Otero I, Pérez-Peñate G, Sala E, Escribano P.

Arch Bronconeumol. 2018 Apr;54(4):205-215. doi: 10.1016/j.arbres.2017.11.014. Epub 2018 Feb 19. English, Spanish.

20.

Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching.

Chamorro V, Morales-Cano D, Milara J, Barreira B, Moreno L, Callejo M, Mondejar-Parreño G, Esquivel-Ruiz S, Cortijo J, Cogolludo Á, Barberá JA, Perez-Vizcaino F.

PLoS One. 2018 Jan 24;13(1):e0191239. doi: 10.1371/journal.pone.0191239. eCollection 2018.

21.

Soluble guanylate cyclase stimulation reduces oxidative stress in experimental Chronic Obstructive Pulmonary Disease.

Paul T, Salazar-Degracia A, Peinado VI, Tura-Ceide O, Blanco I, Barreiro E, Barberà JA.

PLoS One. 2018 Jan 5;13(1):e0190628. doi: 10.1371/journal.pone.0190628. eCollection 2018.

22.

Instrumental drift removal in GC-MS data for breath analysis: the short-term and long-term temporal validation of putative biomarkers for COPD.

Rodríguez-Pérez R, Cortés R, Guamán A, Pardo A, Torralba Y, Gómez F, Roca J, Barberà JA, Cascante M, Marco S.

J Breath Res. 2018 Mar 14;12(3):036007. doi: 10.1088/1752-7163/aaa492.

23.

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study.

McLaughlin VV, Jansa P, Nielsen-Kudsk JE, Halank M, Simonneau G, Grünig E, Ulrich S, Rosenkranz S, Gómez Sánchez MA, Pulido T, Pepke-Zaba J, Barberá JA, Hoeper MM, Vachiéry JL, Lang I, Carvalho F, Meier C, Mueller K, Nikkho S, D'Armini AM.

BMC Pulm Med. 2017 Dec 28;17(1):216. doi: 10.1186/s12890-017-0563-7.

24.

An official European Respiratory Society statement: pulmonary haemodynamics during exercise.

Kovacs G, Herve P, Barbera JA, Chaouat A, Chemla D, Condliffe R, Garcia G, Grünig E, Howard L, Humbert M, Lau E, Laveneziana P, Lewis GD, Naeije R, Peacock A, Rosenkranz S, Saggar R, Ulrich S, Vizza D, Vonk Noordegraaf A, Olschewski H.

Eur Respir J. 2017 Nov 22;50(5). pii: 1700578. doi: 10.1183/13993003.00578-2017. Print 2017 Nov. Erratum in: Eur Respir J. 2018 Jan 18;51(1):.

25.

Cigarette smoke challenges bone marrow mesenchymal stem cell capacities in guinea pig.

Tura-Ceide O, Lobo B, Paul T, Puig-Pey R, Coll-Bonfill N, García-Lucio J, Smolders V, Blanco I, Barberà JA, Peinado VI.

Respir Res. 2017 Mar 23;18(1):50. doi: 10.1186/s12931-017-0530-0.

26.

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.

Coghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, Kuwana M, McLaughlin VV, Peacock AJ, Simonneau G, Vachiéry JL, Blair C, Gillies H, Miller KL, Harris JHN, Langley J, Rubin LJ; AMBITION investigators.

Ann Rheum Dis. 2017 Jul;76(7):1219-1227. doi: 10.1136/annrheumdis-2016-210236. Epub 2016 Dec 30.

27.

Factors controlling groundwater salinization and hydrogeochemical processes in coastal aquifers from southern Spain.

Argamasilla M, Barberá JA, Andreo B.

Sci Total Environ. 2017 Feb 15;580:50-68. doi: 10.1016/j.scitotenv.2016.11.173. Epub 2016 Dec 10.

PMID:
27960117
28.

Effect of targeted therapy on circulating progenitor cells in precapillary pulmonary hypertension.

García-Lucio J, Tura-Ceide O, Del Pozo R, Blanco I, Pizarro S, Ferrer E, Díez M, Coll-Bonfill N, Piccari L, Peinado VI, Barberà JA.

Int J Cardiol. 2017 Feb 1;228:238-243. doi: 10.1016/j.ijcard.2016.11.175. Epub 2016 Nov 9.

PMID:
27865192
29.

Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study.

Hoeper MM, McLaughlin VV, Barberá JA, Frost AE, Ghofrani HA, Peacock AJ, Simonneau G, Rosenkranz S, Oudiz RJ, White RJ, Miller KL, Langley J, Harris JHN, Blair C, Rubin LJ, Vachiery JL.

Lancet Respir Med. 2016 Nov;4(11):894-901. doi: 10.1016/S2213-2600(16)30307-1. Epub 2016 Oct 11.

PMID:
27745818
30.

Correction: Slug Is Increased in Vascular Remodeling and Induces a Smooth Muscle Cell Proliferative Phenotype.

Coll-Bonfill N, Peinado VI, Pisano MV, Párrizas M, Blanco I, Evers M, Engelmann JC, García-Lucio J, Tura-Ceide O, Meister G, Barberà JA, Musri MM.

PLoS One. 2016 Aug 25;11(8):e0162117. doi: 10.1371/journal.pone.0162117. eCollection 2016.

31.

New Biochemical Insights into the Mechanisms of Pulmonary Arterial Hypertension in Humans.

Bujak R, Mateo J, Blanco I, Izquierdo-García JL, Dudzik D, Markuszewski MJ, Peinado VI, Laclaustra M, Barberá JA, Barbas C, Ruiz-Cabello J.

PLoS One. 2016 Aug 3;11(8):e0160505. doi: 10.1371/journal.pone.0160505. eCollection 2016.

32.

Persistence of Breakage in Specific Chromosome Bands 6 Years after Acute Exposure to Oil.

Francés A, Hildur K, Barberà JA, Rodríguez-Trigo G, Zock JP, Giraldo J, Monyarch G, Rodriguez-Rodriguez E, de Castro Reis F, Souto A, Gómez FP, Pozo-Rodríguez F, Templado C, Fuster C.

PLoS One. 2016 Aug 1;11(8):e0159404. doi: 10.1371/journal.pone.0159404. eCollection 2016.

33.

Slug Is Increased in Vascular Remodeling and Induces a Smooth Muscle Cell Proliferative Phenotype.

Coll-Bonfill N, Peinado VI, Pisano MV, Párrizas M, Blanco I, Evers M, Engelmann JC, García-Lucio J, Tura-Ceide O, Meister G, Barberà JA, Musri MM.

PLoS One. 2016 Jul 21;11(7):e0159460. doi: 10.1371/journal.pone.0159460. eCollection 2016. Erratum in: PLoS One. 2016;11(8):e0162117.

34.

Beta-3 adrenergic agonists reduce pulmonary vascular resistance and improve right ventricular performance in a porcine model of chronic pulmonary hypertension.

García-Álvarez A, Pereda D, García-Lunar I, Sanz-Rosa D, Fernández-Jiménez R, García-Prieto J, Nuño-Ayala M, Sierra F, Santiago E, Sandoval E, Campelos P, Agüero J, Pizarro G, Peinado VI, Fernández-Friera L, García-Ruiz JM, Barberá JA, Castellá M, Sabaté M, Fuster V, Ibañez B.

Basic Res Cardiol. 2016 Jul;111(4):49. doi: 10.1007/s00395-016-0567-0. Epub 2016 Jun 21.

35.

Pulmonary vasculature in COPD: The silent component.

Blanco I, Piccari L, Barberà JA.

Respirology. 2016 Aug;21(6):984-94. doi: 10.1111/resp.12772. Epub 2016 Mar 30. Review.

36.

Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry.

Delcroix M, Lang I, Pepke-Zaba J, Jansa P, D'Armini AM, Snijder R, Bresser P, Torbicki A, Mellemkjaer S, Lewczuk J, Simkova I, Barberà JA, de Perrot M, Hoeper MM, Gaine S, Speich R, Gomez-Sanchez MA, Kovacs G, Jaïs X, Ambroz D, Treacy C, Morsolini M, Jenkins D, Lindner J, Dartevelle P, Mayer E, Simonneau G.

Circulation. 2016 Mar 1;133(9):859-71. doi: 10.1161/CIRCULATIONAHA.115.016522. Epub 2016 Jan 29.

PMID:
26826181
37.

Gene expression profile of angiogenic factors in pulmonary arteries in COPD: relationship with vascular remodeling.

García-Lucio J, Argemi G, Tura-Ceide O, Diez M, Paul T, Bonjoch C, Coll-Bonfill N, Blanco I, Barberà JA, Musri MM, Peinado VI.

Am J Physiol Lung Cell Mol Physiol. 2016 Apr 1;310(7):L583-92. doi: 10.1152/ajplung.00261.2015. Epub 2016 Jan 22.

38.

The evolution of shortcomings in Incident Command System: Revisions have allowed critical management functions to atrophy.

Stambler KS, Barbera JA.

J Emerg Manag. 2015 Nov-Dec;13(6):509-18. doi: 10.5055/jem.2015.0260. Review.

PMID:
26750813
39.

Inspiratory capacity-to-total lung capacity ratio and dyspnoea predict exercise capacity decline in COPD.

Ramon MA, Ferrer J, Gimeno-Santos E, Donaire-Gonzalez D, Rodríguez E, Balcells E, de Batlle J, Benet M, Guerra S, Sauleda J, Ferrer A, Farrero E, Gea J, Barberà JA, Agustí A, Rodriguez-Roisin R, Antó JM, Garcia-Aymerich J; PAC-COPD Study Group.

Respirology. 2016 Apr;21(3):476-82. doi: 10.1111/resp.12723. Epub 2015 Dec 30.

40.

Management and outcomes in chronic thromboembolic pulmonary hypertension: From expert centers to a nationwide perspective.

Escribano-Subías P, Del Pozo R, Román-Broto A, Domingo Morera JA, Lara-Padrón A, Elías Hernández T, Molina-Ferragut L, Blanco I, Cortina J, Barberà JA; REHAP Investigators.

Int J Cardiol. 2016 Jan 15;203:938-44. doi: 10.1016/j.ijcard.2015.11.039. Epub 2015 Nov 10.

PMID:
26618257
41.

Gaining insights into pulmonary hypertension in respiratory diseases.

Barberà JA, Blanco I.

Eur Respir J. 2015 Nov;46(5):1247-50. doi: 10.1183/13993003.01288-2015. No abstract available.

42.

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.

Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION Investigators.

N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687.

43.

Follow-Up Genotoxic Study: Chromosome Damage Two and Six Years after Exposure to the Prestige Oil Spill.

Hildur K, Templado C, Zock JP, Giraldo J, Pozo-Rodríguez F, Frances A, Monyarch G, Rodríguez-Trigo G, Rodriguez-Rodriguez E, Souto A, Gómez FP, Antó JM, Barberà JA, Fuster C.

PLoS One. 2015 Jul 29;10(7):e0132413. doi: 10.1371/journal.pone.0132413. eCollection 2015.

44.

Benefits of physical activity on COPD hospitalisation depend on intensity.

Donaire-Gonzalez D, Gimeno-Santos E, Balcells E, de Batlle J, Ramon MA, Rodriguez E, Farrero E, Benet M, Guerra S, Sauleda J, Ferrer A, Ferrer J, Barberà JA, Rodriguez-Roisin R, Gea J, Agustí A, Antó JM, Garcia-Aymerich J; PAC-COPD Study Group.

Eur Respir J. 2015 Nov;46(5):1281-9. doi: 10.1183/13993003.01699-2014. Epub 2015 Jul 23.

45.

Pulmonary hemodynamic profile in chronic obstructive pulmonary disease.

Portillo K, Torralba Y, Blanco I, Burgos F, Rodriguez-Roisin R, Rios J, Roca J, Barberà JA.

Int J Chron Obstruct Pulmon Dis. 2015 Jul 14;10:1313-20. doi: 10.2147/COPD.S78180. eCollection 2015. Erratum in: Int J Chron Obstruct Pulmon Dis. 2015;10:2377.

46.

Non-anaemic iron deficiency impairs response to pulmonary rehabilitation in COPD.

Barberan-Garcia A, Rodríguez DA, Blanco I, Gea J, Torralba Y, Arbillaga-Etxarri A, Barberà JA, Vilaró J, Roca J, Orozco-Levi M.

Respirology. 2015 Oct;20(7):1089-95. doi: 10.1111/resp.12591. Epub 2015 Jul 7. Erratum in: Respirology. 2016 Jan;21(1):196.

47.

Management of Pulmonary Hypertension in Patients with Chronic Lung Disease.

Barberà JA, Blanco I.

Curr Hypertens Rep. 2015 Aug;17(8):62. doi: 10.1007/s11906-015-0574-9. Review.

PMID:
26115628
48.

Transdifferentiation of endothelial cells to smooth muscle cells play an important role in vascular remodelling.

Coll-Bonfill N, Musri MM, Ivo V, Barberà JA, Tura-Ceide O.

Am J Stem Cells. 2015 Mar 15;4(1):13-21. eCollection 2015. Review.

49.

Sildenafil in a cigarette smoke-induced model of COPD in the guinea-pig.

Domínguez-Fandos D, Valdés C, Ferrer E, Puig-Pey R, Blanco I, Tura-Ceide O, Paul T, Peinado VI, Barberà JA.

Eur Respir J. 2015 Aug;46(2):346-54. doi: 10.1183/09031936.00139914. Epub 2015 Apr 30.

50.

Gene and Protein Expression of Fibronectin and Tenascin-C in Lung Samples from COPD Patients.

Muñoz-Esquerre M, Huertas D, Escobar I, López-Sánchez M, Penín R, Peinado V, Barberà JA, Molina-Molina M, Manresa F, Dorca J, Santos S.

Lung. 2015 Jun;193(3):335-43. doi: 10.1007/s00408-015-9717-7. Epub 2015 Mar 21.

PMID:
25794567

Supplemental Content

Loading ...
Support Center